Welcome to our dedicated page for Passage BIO SEC filings (Ticker: PASG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Passage Bio, Inc. SEC filings document a clinical-stage genetic medicines issuer focused on PBFT02 for neurodegenerative diseases. Form 8-K reports cover financial results, Regulation FD presentations, PBFT02 clinical and regulatory updates, lease termination matters, and exit or disposal activity affecting operating costs.
Proxy materials disclose board composition, audit committee changes, executive compensation, and equity-award governance. The filing record also identifies the company's public reporting status, Delaware incorporation, Nasdaq listing venue, and recurring capital-resource disclosures tied to development-stage biotechnology operations.
Passage Bio files its annual report describing progress on PBFT02, a gene therapy for frontotemporal dementia caused by progranulin deficiency (FTD-GRN) and related neurodegenerative diseases. In a Phase 1/2 trial, Dose 1 of PBFT02 raised cerebrospinal fluid progranulin from below 3.0 ng/mL at baseline to means of 12.4 ng/mL at one month, 19.4 ng/mL at six months, 25.9 ng/mL at 12 months and 23.8 ng/mL at 18 months, above healthy control ranges. Plasma neurofilament light chain, a marker of neurodegeneration, increased 4% at 12 months versus natural-history increases of about 28–29%. Safety data showed treatment-related venous sinus thrombosis and hepatotoxicity at the higher dose, which were asymptomatic and responsive to treatment. The company is now enrolling a lower-dose Cohort 3, extending PBFT02 development into FTD with C9orf72 mutations, and positioning a higher-yield suspension manufacturing process with Catalent for late-stage trials. Passage Bio also highlights an HD program with Gemma Biotherapeutics targeting MSH3 to reduce somatic instability, plus orphan and Fast Track designations for PBFT02 in FTD.
Passage Bio reported fourth-quarter and full-year 2025 results and highlighted progress in its PBFT02 gene therapy program for frontotemporal dementia. The company enrolled the first three FTD-GRN patients in Cohort 3 and treated the first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of the upliFT-D study.
Net loss for 2025 was $45,522 thousand, narrowing from $64,767 thousand in 2024, as research and development expenses fell to $23,276 thousand from $40,179 thousand and general and administrative expenses declined to $19,875 thousand from $24,988 thousand. Cash and cash equivalents were $46,303 thousand at December 31, 2025, and the company projects a cash runway through the first quarter of 2027.
The upliFT-D Phase 1/2 trial continues to enroll FTD-GRN and FTD-C9orf72 patients, focusing primarily on safety and tolerability, with biomarker and clinical outcomes as secondary measures. Passage Bio plans updated interim safety and biomarker data and regulatory feedback on an FTD-GRN registrational trial design in the first half of 2026, and expects to select a clinical candidate for its Huntington’s program in the second half of 2026.
Passage BIO, Inc. reported an insider equity transaction by President and CEO William Chou. On January 8, 2026, 10,000 restricted stock units converted into an equal number of common shares at an exercise price of $0. In connection with this vesting, 4,076 common shares were sold at a weighted average price of $18.4394 per share as part of an issuer-mandated "sell to cover" transaction to satisfy tax withholding obligations, rather than a discretionary sale.
After these transactions, Chou directly held 6,524 common shares and 10,000 RSUs. The RSUs vest in two equal installments, with 50% scheduled to vest on January 8, 2026 and the remaining 50% on January 8, 2027, subject to continued service with Passage BIO.
Passage BIO, Inc. CFO Kathleen Borthwick reported the vesting of equity awards and an associated tax sale. On January 8, 2026, 5,000 restricted stock units converted into common stock at an exercise price of $0, reflecting previously granted compensation.
On the same date, she sold 2,062 shares of common stock at a weighted average price of $18.4394 per share, in an issuer-mandated “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting. The price for these shares came from multiple trades between $18.13 and $19.3061 per share. After these transactions, she directly held 5,402 shares of common stock and 5,000 RSUs.
Passage Bio, Inc. reported in an updated corporate presentation that its preliminary, unaudited cash, cash equivalents and marketable securities position as of December 31, 2025 was approximately $46 million. The company currently expects this cash balance to be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027. These figures were prepared by management, may change as year-end financial statements are finalized, and remain subject to normal review and audit procedures. The updated corporate presentation containing this information has been furnished as an exhibit and is not deemed filed for liability purposes.
A shareholder of PASG has filed a Form 144 notice to potentially sell 4,076 shares of common stock through broker Maxim Group on NASDAQ. The shares to be sold have an aggregate market value of 75,120.00, compared with 3,178,710 shares of the same class reported as outstanding, and the filer lists an approximate sale date of 01/09/2026.
The securities were originally acquired as restricted stock from the issuer on 01/15/2025, with 10,000 shares obtained as compensation and a stated payment date of 01/09/2026. By signing the notice, the selling holder represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
Passage Bio (PASG) filed its Q3 2025 10‑Q, reporting lower operating costs and a narrower loss. Net loss was $7.7 million for the quarter and $32.5 million year‑to‑date, reflecting reduced research and development and general and administrative spending after a January workforce reduction. Other income was supported by interest on cash and sublease income.
Cash and cash equivalents were $52.8 million, up from $37.6 million at year‑end as marketable securities matured and were reinvested in money market funds. Total assets were $74.2 million and total liabilities were $43.0 million, leaving stockholders’ equity at $31.1 million. The company recorded $13.8 million of non‑refundable sublicense and transition services payments related to its Gemma agreements as a current liability, with revenue recognition deferred. Management states cash is sufficient for at least the next 12 months. As of November 6, 2025, 3,178,710 common shares were outstanding. The at‑the‑market facility had $15.8 million of remaining capacity at September 30, 2025.
Passage Bio, Inc. filed a current report to note it issued a press release announcing financial results for the quarter ended September 30, 2025 and updated its corporate presentation.
The press release is furnished under Item 2.02 as Exhibit 99.1, and the presentation is furnished under Item 7.01 as Exhibit 99.2. Both items are furnished, not filed, and are not incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Kathleen Borthwick.
Passage Bio, Inc. reported that on September 16, 2025, board member Saqib Islam resigned from its Board of Directors and from the Board’s Audit Committee, effective immediately. The company stated that his decision was not due to any disagreement with Passage Bio on matters related to operations, policies, or practices.
To address the vacancy, the Board appointed Athena Countouriotis, M.D., to serve on the Audit Committee and reduced the overall Board size from eight to seven members as of the resignation date.
Passage BIO, Inc. (PASG) Form 4: Lynx1 Capital Management LP and Weston Nichols reported insider purchases of Passage BIO common stock on three dates in September 2025. The filings show acquisitions of 325 shares on 09/11/2025 at a weighted average price of $6.9558 (range $6.915–$6.985), 19,783 shares on 09/12/2025 at $6.9908 (range $6.93–$7.00), and 11,900 shares on 09/15/2025 at $6.9895 (range $6.94–$7.00). Following these transactions, the filing reports beneficial ownership of 623,704 shares held indirectly through Lynx1 Master Fund LP, for which Lynx1 Capital Management LP is the investment manager and Weston Nichols is the sole member of the manager's GP. The reporting persons are identified as a director and a 10% owner.